Penumbra, Inc. reported a 14.9% revenue increase to $390 million in Q2 2026, driven by growth in thrombectomy and embolization products. The company posted $34.8 million net income despite acquisition-related expenses linked to its pending purchase by Boston Scientific. Penumbra will not provide full-year guidance or hold a conference call due to the acquisition process. This financial performance highlights Penumbra's strong market position ahead of the acquisition completion.
Boston Scientific reported solid Q2 2026 results with 7.5% sales growth and 14.7% adjusted EPS growth, driven by strong international demand, particularly in electrophysiology and WATCHMAN devices. Despite facing growth headwinds in the U.S., the com...
Boston Scientific Corporation announced it will participate in Wells Fargo's 21st Annual Healthcare Conference on September 10, 2026, with CEO Mike Mahoney and CMO Kenneth Stein leading a Q&A session. The company will also release its financial resul...
